Alyeska Investment Group
LUCD icon

Alyeska Investment Group’s Lucid Diagnostics LUCD Stock Holding History

Alyeska Investment Group’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.48M Buy
+8,856,844
New +$9.55M 0.02% 436
2025
Q4 		– Sell
-1,383,116
Closed -$1.4M – 670
2025
Q3 		$1.4M Buy
1,383,116
+644,839
+87% +$704K ﹤0.01% 527
2025
Q2 		$849K Sell
738,277
-1,149,566
-61% -$1.48M ﹤0.01% 511
2025
Q1 		$2.81M Buy
+1,887,843
New +$2.27M 0.01% 401

Other funds holding LUCD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Alyeska Investment Group's LUCD Position: Q2 2026 in Review

Alyeska Investment Group opened a new position in Lucid Diagnostics (LUCD) in Q2 2026: 8,856,844 shares worth $9.48M. The stake represents 0.02% of the portfolio and ranks #436 among its holdings. This is a return to the name: Alyeska Investment Group previously reported a position in LUCD as recently as Q3 2025.

Alyeska Investment Group first reported a position in LUCD in Q1 2025 and has held it in 4 quarters since. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Alyeska Investment Group held 8,856,844 shares of Lucid Diagnostics worth $9.48M as of Q2 2026.
  • Lucid Diagnostics was a new Alyeska Investment Group position in Q2 2026.
  • Lucid Diagnostics made up 0.02% of Alyeska Investment Group's portfolio in Q2 2026, its #436 holding.
  • Alyeska Investment Group first reported a position in Lucid Diagnostics in Q1 2025 and has held it in 4 quarters since.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.